The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review.

Curr Ther Res Clin Exp · 2020 · PMC7424199 · PMID 32817765

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The renal efficacy end point showed a trend toward linagliptin reducing the time-weighted average of percentage change from baseline in UACR over 24 weeks compared with placebo (–11% vs –5.1%, respectively).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.